To better corroborate these results, we used the LIMORE database17 which included the half maximal inhibitory concentration of lenvatinib and KDM6A expression in 31 public cell lines and 50 new cell models established from Chinese liver cancer patients to evaluate the efficacy of lenvatinib in HCC cells with different KDM6A expression. This evidence concerns the gene KDM6A and liver cancer.